BioSyent Inc. (BIOYF)

Market Cap	88.36M
Revenue (ttm)	24.08M
Net Income (ttm)	5.17M
Shares Out	11.80M
EPS (ttm)	0.43
PE Ratio	17.31
Forward PE	18.36
Dividend	$0.13 (1.76%)
Ex-Dividend Date	May 31, 2024

Volume	100
Open	7.49
Previous Close	7.49
Day's Range	n/a
52-Week Range	5.49 - 7.76
Beta	0.95
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About BIOYF

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: René C. Goehrum
• Founded: 1947
• Stock Exchange: OTCMKTS
• Ticker Symbol: BIOYF

Financial Performance

In 2023, BioSyent's revenue was 31.59 million, an increase of 13.12% compared to the previous year's 27.93 million. Earnings were 6.46 million, an increase of 18.35%.

Financial numbers in CAD